Gene Array Subjects

SUBJECTS ARRANGED ACCORDING TO GROUP ASSIGNMENT

Groups:
Group A
Group B
Group C
Group D
HIV Infection:
HIV Negative
HIV Infected
HIV Infected
HIV Infected
Neurocognitive Impairment +/-:
(Not Impaired)
Not Impaired
Impaired
Impaired
Global Impairment Score*:
N/A
2.4 ± 1.3
7.1± 0.6
7.5 ± 1.3
Neurocognitive Diagnosis**:
NL = 6
NL = 5
SUB = 1

HAD=1
PROB HAD=1
POSS HAD=2
MCMD=3

HAD = 3
PROB HAD=1
PROB MCMD=1
HIV Encephalitis (HIVE) +/-:
No HIVE
No HIVE
No HIVE
HIVE

CNS HIV RNA Concentration
(log10 copies/gram wet weight)

 

White Matter, Deep Frontal:

0
3.53 ± 0.69
3.85 ± 2.54
7.40 ± 1.80

Striatium:

0
3.84 ± 0.50
3.51 ± 1.37
7.27 ± 0.84

Frontal Neocortex:

0
3.65 ± 0.74
3.63 ± 1.12
6.16 ± 1.34
NNTC Subject Number:
A1
A2
A3
A4
A5
A6
B1
B2
B3
B4
B5
B6
C1
C2
C3
C4
C5
C6
C7
D1
D2
D3
D4
D5
Geographical Breakdown***:
NYC = 3
TEX = 2
UCSD = 1
UCLA = 0

NYC = 1
TEX = 2
UCSD = 2
UCLA = 1

NYC = 1
TEX = 2
UCSD = 2
UCLA = 2
NYC = 1
TEX = 2
UCSD = 2
UCLA = 0
Age (years ± SD) :
50.0 ± 10.4
49.7 ± 8.3
43.7 ± 9.8
43.0 ± 8.8
Race or Ethnicity****:
WT = 5
BL = 0
AS = 0
HP = 1

WT = 6
BL = 0
AS = 0
HP = 0

WT = 4
BL = 1
AS = 0
HP = 2

WT = 4
BL = 0
AS = 0
HP = 1

Gender (Male/Female):
M = 5; F = 1
M = 6; F = 0
M = 7; F = 0
M = 5, F = 0
Brain Freeze Time (hours):
18.7 ± 5.1
17.3 ± 16.3
7.2 ± 2.1
10.5 ± 4.2

* Global Impairment Score is an index of overall performance on the NNTC neuropsychological test battery. A score <4 is considered normal; a score >7 indicates impairment severe enough to be classified as dementia.
** HAD = HIV-associated dementia; MCMD = Minor Cognitive and Motor Disorder; Subsyndromic = Mildy abnormal test performance without symptoms of impairment.
*** Geographical locations in the United States of America: NYC = New York City; TEX = Galveston/Houston, Texas; UCSD = San Diego, California; UCLA = Los Angeles, California.
**** WT = Caucasian; BL = African American; AS = Asian; HP = Hispanic



SUBJECTS ARRANGED ACCORDING TO SELECTION CRITERIA

Original Identifier
Impairment Score
Age (Year)
Race
Gender
ARV Exposure
Freeze time (hours)
Diagnosis
Group A
A1
N/A
44
White
M
Not applicable
21.5
Normal
A2
N/A
53
White
M
Not applicable
22.5
Normal
A3
N/A
63
Hispanic
M
Not applicable
19.0
Normal
A4
N/A
58
White
M
Not applicable
13.0
Normal
A5
N/A
34
White
M
Not applicable
24.0
Normal
A6
N/A
48
White
F
Not applicable
12.0
Normal
Total/Averages
N/A
50.0
W=5
H=1
M=5
F=1
18.7
Normal=6
Group B
B1
4
49
White
M
3TC, APV, D4T, DDI,
IDV, KTA, NVP, RTV,
SQV, ZDV
6.0
Normal
B2
3
47
White
M
3TC, ABC, APV, D4T,
DDC, DDI, EFV, HU,
IDV, KTA, NFV, NVP,
RTV, SQV, T20, TFV,
ZDV
4.6
Normal
B3
3
44
White
M
3TC, ABC, ATV, D4T,
NFV, NVP, RTV, SQV,
TRU
22.3
Normal
B4
1
59
White
M
3TC, D4T, KTA,
RTV, TFV
12.0
Subsyndromic
B5
1
60
White
M
3TC, APV, D4T, DDI,
EFV, IDV, NVP, RTV,
TFV, ZDV
48.0
Normal
B6
Normal
39
White
M
3TC, ABC, D4T, EFV,
IDV, KTA, NVP
11.0
Normal
Total/Averages
2.4
49.7
W=6
M=6
F=0
17.3
Normal=5
Subsyndromic=1
Group C
C1
7
33
Black
M
3TC, ABC, APV, D4T,
DDI, EFV, IDV, KTA,
NVP, RTV, SQV, TFV,
TZV, ZDV
6.0
"Possible HAD"
C2
6
35
White
M
No ARV exposure history
11.3
MCMD
C3
7
57
White
M
3TC, D4T, DDI, NFV,
ZDV
6.8
"Possible HAD"
C4
7
36
Hispanic
M
No ARV exposure history
9.0
MCMD
C5
7
52
White
M
3TC, D4T, NFV
6.0
MCMD
C6
8
41
White
M
3TC, ABC, D4T, FTV,
IDV, KTA, ZDV
5.5
"Probable HAD"
C7
8
52
Hispanic
M
APV, CBV, KTA, NVP,
TFV
6.0
HAD
Total/Averages
7.1
43.7
W=4
H=2
B=1
M=7
F=0
7.2
MCMD=3
HAD=4
Group D
D1
6
48
White
M
APV, CBV, D4T, EFV,
NFV, RTV
7.5
"Probable MCMD"
D2
9
32
White
M
3TC, CBV, D4T, NPV, ZDV
14.5
HAD
D3
Severe
39
White
M
3TC, ABC, D4T, DDI,
EFV, IDV, NFV, ZDV
5.5
HAD
D4
8
55
White
M
ARV exposure,
medications unknown
15.0
HAD
D5
7
41
Hispanic
M
ARV exposure,
medications unknown
10.0
"Probable HAD"
Total/Averages
7.5
43.0
W=4
H=1
M=5
F=0
10.5
MCMD=1
HAD=4

 

GENOMICS LABORATORY SAMPLE IDENTIFICATION CODE

#s 1 to 24
WHITE MATTER
#s 25 to 48
FRONTAL CORTEX
#s 49 to 72
BASAL GANGLIA
Group A WM-A1-01 FC-A1-25 BG-A1-49
WM-A2-02 FC-A2-26 BG-A2-50
WM-A3-03 FC-A3-27 BG-A3-51
WM-A4-04 FC-A4-28 BG-A4-52
WM-A5-05 FC-A5-29 BG-A5-53
WM-A6-06¶ FC-A6-30 BG-A6-54
Group B WM-B1-07 † FC-B1-31 BG-B1-55
WM-B2-08 FC-B2-32 BG-B2-56
WM-B3-09 FC-B3-33 BG-B3-57
WM-B4-10 FC-B4-34 BG-B4-58
WM-B5-11 †¶ FC-B5-35 †¶ BG-B5-59 †¶
WM-B6-12 †¶ FC-B6-36 †¶ BG-B6-60 †¶
Group C WM-C1-13 FC-C1-37 BG-C1-61
WM-C2-14 FC-C2-38 BG-C2-62
WM-C3-15 FC-C3-39 BG-C3-63
WM-C4-16 FC-C4-40 BG-C4-64
WM-C5-17 FC-C5-41 BG-C5-65 †¶
WM-C6-18 † FC-C6-42 BG-C6-66
WM-C7-19 † FC-C7-43 BG-C7-67
Group D WM-D1-20 FC-D1-44 BG-D1-68
WM-D2-21 FC-D2-45 BG-D2-69
WM-D3-22 FC-D3-46 BG-D3-70
WM-D4-23 FC-D4-47 BG-D4-71
WM-D5-24 FC-D5-48 BG-D5-72

Last two digits: A unique sample identifier used by the UTMB Molecular Genomics Laboratory.

The samples are labeled from 1 through 72.

† Denotes that the isolated RNA had potentially significant hydrolysis when analyzed using gel chromatography, which showed evidence of RNA fragments with reduced size. Some, but not all samples with evidence of hydrolysis eventually exhibited evidence of atypical hybridization patterns on the array. See below.

¶ Denotes that the hybridization signal pattern of this sample was influenced by RNA degradation when it was analyzed. One or more outcomes were used to screen for anomalous hybridization on a particular chip. See 6.0 for details. Briefly, a hybridization signal sometimes was present in a relatively high percentage of all the probe sets; alternatively signal intensities were weak across the board and required a high scaling factor for calibration. Both of those indexes suggest that probe sets that did not produce a significant hybridization signal in most of the samples might erroneously report that the signal is present on these particular chips. Another problem index is when spiked control RNA showed an uneven distribution of cDNA representation, due to uneven conversion to cDNA. This means that the effectiveness of hybridization of some transcripts on the chip, but not all transcripts on the chip, may have been corrupted due to RNA degradation. These errors can produce over- or under-representation of certain signal intensities relative to the other transcripts on the array.

BOLD denotes that these two cases were added to compensate for cases that had preliminary evidence of potentially substantial RNA degradation.